Copyright © 2004 by the European Society of Cardiology.
Clinical research
Effect of candesartan on New York Heart Association functional class
Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
a Department of Cardiology, Western Infirmary, Glasgow, Scotland, UK
b Brigham & Women's Hospital, Boston, MA, USA
c HGM-McMaster Clinic, Hamilton, Ontario, Canada
d AstraZeneca LP, Wilmington, DE, USA
e Duke University Medical Center, Durham, NC, USA
f AstraZeneca, R&D Mölndal, Sweden
g Medicine, Cleveland Clinic Foundation, Cleveland, USA
h Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden
Received March 25, 2004; revised July 8, 2004; accepted July 15, 2004 * Corresponding author. Tel.: +44 141 211 1838; fax: +44 141 211 2252 (E-mail: j.mcmurray{at}bio.gla.ac.uk).
AIMS: To evaluate the effect of the angiotensin receptor blocker candesartan on New York Heart Association (NYHA) functional class in a broad spectrum of patients with chronic heart failure (CHF).
METHODS AND RESULTS: Patients in the CHARM Programme with symptomatic CHF were randomized to placebo (n=3796) or candesartan (n=3803) and followed for a median of 38 months. NYHA class was assessed at baseline, at two weekly intervals during dose titration and 4 monthly thereafter. Patients were classified as "better", "unchanged" or "worse" at the end of the study compared to baseline. Both a simple "last visit carried forward" (LVCF) analysis and "worst rank carried forward" (WRCF) analysis (where patients who died were allocated NYHA class V) were used. In the LVCF analysis, compared to placebo, more candesartan patients improved (35.4% versus 32.5%) and fewer worsened (9.0% versus 10.3%) in NYHA class (p=0.003). The WRCF analysis also showed a better overall change in NYHA class with candesartan compared to placebo. There was no heterogeneity in the response to candesartan between the CHARM component trials.
CONCLUSIONS: Candesartan improves NYHA functional class to a similar extent to other proven treatments for CHF when added to these other treatments.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Fogari, A. Mugellini, and G. Derosa Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 139 - 144. [Abstract] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor, and on behalf of PEP-CHF Investigators The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur. Heart J., October 1, 2006; 27(19): 2338 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, F. L. Andersson, S. Stewart, K. Svensson, A. C. Solal, R. Dietz, J. Vanhaecke, D. J. van Veldhuisen, J. Ostergren, C. B. Granger, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. Heart J., June 1, 2006; 27(12): 1447 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McMurray Review: Optimising the use of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2_suppl): S2 - S5. [Abstract] [PDF]
|
|